Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...